Ovarian Cancer Clinical Trial
Official title:
Randomized Phase II AGO-Study Comparing Combined Liposomal Doxorubicin (Myocet) and Gemcitabine (Gemzar) With Liposomal Doxorubicin (Myocet) Monotherapy in Platinum-Refractory and Platinum-Resistant Epithelial Cancer of the Ovary, Fallopian Tube and the Peritoneum
Verified date | April 2010 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | Unspecified |
Study type | Interventional |
RATIONALE: Drugs used in chemotherapy, such as liposome-encapsulated doxorubicin citrate and
gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either
by killing the cells or by stopping them from dividing. It is not yet known whether
liposome-encapsulated doxorubicin citrate is more effective when given together with or
without gemcitabine hydrochloride in killing tumor cells.
PURPOSE: This randomized phase II trial is studying liposome-encapsulated doxorubicin
citrate given together with gemcitabine hydrochloride to see how well it works compared with
liposome-encapsulated doxorubicin citrate alone in treating patients with ovarian epithelial
cancer, fallopian tube cancer, or primary peritoneal cavity cancer.
Status | Recruiting |
Enrollment | 154 |
Est. completion date | |
Est. primary completion date | May 2014 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer - Progression or recurrence during first-line platinum-based chemotherapy (platinum-refractory disease) OR progression or recurrence during the first 6 months following the end of the last platinum-containing chemotherapy (platinum-resistant disease) - Meets = 1 of the following criteria: - Measurable metastatic disease on CT or MRI scan, ultrasound, or chest x-ray - Evaluable disease on CT/MRI scan (e.g., ascites or pleural effusion) or chest x-ray (e.g., pleural effusion) - Tumor marker progression (CA-125) according to Rustin criteria, meeting 1 of the following criteria: - CA-125 > 2 times upper limit of normal (UNL) - CA-125 > 2 times nadir value on two occasions - No ovarian carcinosarcoma (malignant mixed Müllerian tumor) or pure sarcoma PATIENT CHARACTERISTICS: - Karnofsky performance status 70-100% - Life expectancy = 3 months - Platelet count = 100,000/mm³ - Hemoglobin = 10 g/dL - Neutrophil count = 1.5 x 10³/mm³ - Serum creatinine < 1.5 times ULN - Bilirubin < 1.5 times ULN (< 2.5 times ULN if liver metastases are present) - AST/ALT < 2.5 times ULN (unless caused by parenchymal liver metastases) - No childbearing capacity - LVEF = 50% by ECHO or MUGA scan - No significant comorbidity (e.g., uncontrolled infection, clinical signs of cardiac insufficiency, history of myocardial infarction, or cardiac rhythmic disorders [NYHA class III-IV disease]) - No known hypersensitivity to study drugs - No active secondary malignant tumor within the past 5 years (e.g., metastases from primary breast cancer) - No condition (medical, social, or psychological), that would prevent adequate follow-up PRIOR CONCURRENT THERAPY: - No prior chemotherapy with pegylated liposomal doxorubicin hydrochloride, other anthracyclines, or gemcitabine hydrochloride - No other concurrent tumor-specific therapy for ovarian cancer |
Allocation: Randomized, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Austria | Innsbruck Universitaetsklinik | Innsbruck |
Lead Sponsor | Collaborator |
---|---|
Medical University Innsbruck |
Austria,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Remission rates (complete response and partial response) | No | ||
Secondary | Quality of life as measured by EORTC-QLQ30 and QLQ-OV28 questionnaires | No | ||
Secondary | Progression-free survival | No | ||
Secondary | Overall survival | No | ||
Secondary | Toxicity | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |